A clinical hold on Phase I/II research into stem cell therapy VX-880 has left executives at Vertex Pharmaceuticals (Nasdaq: VRTX) scratching their heads.
The investigational stem cell-derived treatment for people with type 1 diabetes (T1D) has been generally well tolerated to date, with no serious adverse events considered related to the study drug.
The US Food and Drug Administration has however determined that there is “insufficient information to support dose escalation with the product,” resulting in the trial stoppage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze